VTX958 Versus Placebo for the Treatment of Active Psoriatic Arthritis (Tranquility-PsA)

Phase 2

Terminated

• Conditions: Psoriatic Arthritis
• Interventions: Drug: Dose B VTX958; Drug: Placebo; Drug: Dose A VTX958

• Registration Number: NCT05715125
• Lead Sponsor: Ventyx Biosciences, Inc

Brief Summary

The objective of this study is to evaluate if VTX958 is safe and effective in adult participants with active Psoriatic Arthritis. Approximately 195 eligible participants will take VTX958 Dose A, VTX958 Dose B, or matching placebo (no active drug) for 16 weeks and then move on to a 36 week Long Term Extension (LTE). The study will include 16 weeks of treatment, 36 weeks of LTE, and a 30-day follow-up period.

Detailed Description

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two doses of VTX958 tablets, Dose A and Dose B, in adults with active Psoriatic Arthritis. Approximately 195 participants will be assigned in a 1:1:1 ratio to one of three groups, VTX958 Dose A, VTX958 Dose B, or placebo, for 16 weeks and then move on to a 36 week Long Term Extension (LTE). The study consists of a 30-day screening period, a 16 week double-blind treatment period, 36 weeks of LTE, and a 30 day follow-up period.

Study Timeline

• Study First Submitted: 2023-01-19
• Study Start: 2023-01-31
• Study First Submitted QC: 2023-02-04
• Study First Posted: 2023-02-06
• Primary Completion: 2024-01-02
• Study Completion: 2024-01-02
• Status Verified: 2024-12
• Disposition First Submitted: 2024-12-23
• Last Update Submitted: 2024-12-23
• Disposition First Posted: 2024-12-27
• Last Update Posted: 2024-12-27

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 205

Inclusion Criteria

• Diagnosed with Psoriatic Arthritis for 6 months or more prior to Screening
• Documented history or active signs of at least 1 confirmed lesion of plaque psoriasis and/or nail changes attributed to psoriasis
• Active PsA as defined by 3 or more swollen joints and 3 or more tender joints at Screening and Day 1
• Women must not be of childbearing potential or must agree to use a highly effective contraception during the study and for 30 days after the last dose of the study product
• Men with a partner who is of childbearing potential must agree to use condoms during the study and for 90 days after the last dose of study product

Read More

Exclusion Criteria

• Has non-plaque psoriasis at Screening or Day 1
• Has inflammatory bowel disease or active uveitis
• Has a history of chronic or recurrent infectious disease
• Has a known immune deficiency or is immunocompromised
• Has hepatitis B or hepatitis C infection, human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS), or active tuberculosis (TB) at screening

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
VTX958 Dose B	Dose B VTX958	-
Placebo	Placebo	-
VTX958 Dose A	Dose A VTX958	-

Primary Outcome Measures

Name	Time	Method
Proportion of participants achieving 20% improvement in American College of Rheumatology criteria (ACR20) at Week 16	Week 16	Number of participants reaching ACR20 at week 16, compared to the total number of participants in each cohort
Incidence of Treatment Emergent Adverse Events (TEAEs) from week 0 through week 16	Week 16	The number and proportion of participants who have at least 1 TEAE after exposure to the study drug

Secondary Outcome Measures

Name	Time	Method
Proportion of participants achieving 70% improvement in American College of Rheumatology criteria (ACR70) at Week 16	Week 16	Number of participants reaching ACR70 at week 16, compared to the total number of participants in each cohort
Change from baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) scores at Week 16	Week 16	HAQ-DI assesses functional ability. It is a 20 question instrument that assesses the degree of difficulty with accomplishing tasks in 8 functional areas (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities of daily living). Responses in each functional area are scored from 0 (no difficulty) to 3 (inability to perform a task in that area). The overall HAQ-DI score is the mean of the 8 functional area scores and ranges from 0 to 3. Lower scores are indicative of improved functional ability.
Proportion of participants achieving 75% reduction in the Psoriasis Area and Severity Index (PASI75) score at Week 16, in participants with at least 3% body surface area (BSA) involvement at baseline	Week 16	PASI is used to assess the severity of psoriasis and response to therapy. Each body region is evaluated separately for body surface area percentage of involvement and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement) and for erythema, induration, and scaling, each is rated on scale of 0 to 4 (from none to maximum severity). PASI numeric scores range from 0 (no psoriasis) to 72 (maximal disease). Higher scores indicate more severe disease.
Change from baseline in Short Form Health Survey - 36 items (SF-36) physical component score (PCS) at Week 16	Week 16	SF-36 is a 36-item, patient-reported measure of health status and quality of life, which includes 8 domains (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health). Each of the 8 domains contribute in different proportions to the physical component summary (PCS) score and the mental component summary (MCS) score, which are normalized to general US population norms and range from 0 to 100 (where higher scores correspond to a better quality of life).
Proportion of participants achieving 50% improvement in American College of Rheumatology criteria (ACR50) at Week 16	Week 16	Number of participants reaching ACR50 at week 16, compared to the total number of participants in each cohort

Trial Locations

Locations (46)

Site # 616006; 🇵🇱 Warszawa, Poland

Site # 616013; 🇵🇱 Lublin, Poland

Site # 616008; 🇵🇱 Toruń, Poland

Site # 616007; 🇵🇱 Katowice, Poland

Site # 616002; 🇵🇱 Nadarzyn, Poland

Site # 840008; 🇺🇸 South Charleston, West Virginia, United States

Site # 616004; 🇵🇱 Poznań, Poland

Site #616001; 🇵🇱 Warszawa, Poland

Site # 616010; 🇵🇱 Kraków, Poland

Site # 616009; 🇵🇱 Łódź, Poland

Site # 616003; 🇵🇱 Wrocław, Poland

Site # 616014; 🇵🇱 Łódź, Poland

Site # 840011; 🇺🇸 Beckley, West Virginia, United States

Site # 100001; 🇧🇬 Plovdiv, Bulgaria

Site # 100002; 🇧🇬 Plovdiv, Bulgaria

Site # 840015; 🇺🇸 Mesquite, Texas, United States

Site # 840019; 🇺🇸 Eagan, Minnesota, United States

Site # 616011; 🇵🇱 Olsztyn, Poland

Site # 203003; 🇨🇿 Pardubice, Czechia

Site # 348004; 🇭🇺 Kistarcsa, Hungary

Site # 616015; 🇵🇱 Gdynia, Poland

Site # 276002; 🇩🇪 Berlin, Germany

Site # 724001; 🇪🇸 Sevilla, Spain

Site # 276001; 🇩🇪 Hamburg, Germany

Site # 203002; 🇨🇿 Zlín, Czechia

Site # 840007; 🇺🇸 Duncansville, Pennsylvania, United States

Site # 840010; 🇺🇸 Baytown, Texas, United States

Site # 616016; 🇵🇱 Wrocław, Poland

Site # 616012; 🇵🇱 Łódź, Poland

Site # 840006; 🇺🇸 Lubbock, Texas, United States

Site # 203005; 🇨🇿 Praha 5, Czechia

Site # 100004; 🇧🇬 Haskovo, Bulgaria

Site # 840003; 🇺🇸 Middleburg Heights, Ohio, United States

Site # 348003; 🇭🇺 Budapest, Hungary

Site # 348001; 🇭🇺 Hódmezővásárhely, Hungary

Site # 724005; 🇪🇸 Lleida, Spain

Site # 724002; 🇪🇸 A Coruña, Spain

Site # 840014; 🇺🇸 Miami Lakes, Florida, United States

Site # 840001; 🇺🇸 Phoenix, Arizona, United States

Site # 840004; 🇺🇸 Clearwater, Florida, United States

Site # 840016; 🇺🇸 Newport Beach, California, United States

Site # 840017; 🇺🇸 Lexington, Kentucky, United States

Site # 840018; 🇺🇸 Okemos, Michigan, United States

Site #840012; 🇺🇸 Saint Clair Shores, Michigan, United States

Site # 203001; 🇨🇿 Ostrava, Czechia

Site # 203004; 🇨🇿 Hlučín, Czechia